Healthiness Of Actors In DTC Spots Returns As Issue As FDA Cites Aricept Ads
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer, which co-markets the Alzheimer's treatment with Eisai, could feel the biggest impact of the notice of violation due to its settlement with state attorneys general.
You may also be interested in...
Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China
The PharmAsia News Japanese earnings roundup is a periodic feature highlighting major developments from Japanese pharma quarterly calls and reports. The prior installment discussed recent developments at Shionogi & Co. Ltd. and Astellas Pharma Inc. ('Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning,' PharmAsia News, Aug. 2, 2011).
FDA Advertising Enforcers Have Little Patience For "Well Tolerated" Drug Claims
Term is too vague for promotional use, regulators say, but it is not always cited as a violation, even when other aspects of the advertisement are.
FDA Advertising Enforcers Have Little Patience For "Well Tolerated" Drug Claims
Term is too vague for promotional use, regulators say, but it is not always cited as a violation, even when other aspects of the advertisement are.